| Name | Title | Contact Details |
|---|
Proudly celebrating its 75th anniversary in 2013, Independence Blue Cross is the leading health insurer in southeastern Pennsylvania. With our affiliates, we have 3.1 million members nationwide. We are enhancing the health and wellness of the people and communities we serve by delivering innovative and competitively priced health care products and services; pioneering new ways to reward doctors, hospitals, and other health care professionals for coordinated, quality care; and supporting programs and events that promote wellness.
Grapefruit offers Health & Wellness Solutions including telehealth, tele-psychiatry/therapy, and behavioral health services. Having worked with school districts across the country during the pandemic, Grapefruit understands the administrative burdens the schools faced during the pandemic. Grapefruit knows that a successful, comprehensive program should include access along the continuum of care — from health promotion and prevention, to treatment. With a comprehensive telemedicine program, schools have the ability to address both the physical and behavioral needs of each child. Guidance Counselors, school nurses and the school administration are not equipped or trained to handle the increased need for mental and behavioral health our youth is plagued with. Grapefruit recognizes the critical nature of providing these services to children and young adults, now more than ever.
STS North America (Sterilizer Technical Specialists East) is a Chagrin Falls, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prime Medica is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.